| アブストラクト | BACKGROUND: The economic impact of managing long COVID in primary care is unknown. We estimated the costs of primary care consultations associated with long COVID and explored the relationship between risk factors and costs. METHODS: Data were obtained on non-hospitalised adults from the Clinical Practice Research Datalink Aurum primary care database. We used propensity score matching with an incremental cost method to estimate additional primary care consultation costs associated with long COVID (12 weeks after COVID-19) at an individual and UK national level. We applied multivariable regression models to estimate the association between risk factors and consultations costs beyond 12 weeks from acute COVID-19. RESULTS: Based on an analysis of 472,173 patients with COVID-19 and 472,173 unexposed individuals, the annual incremental cost of primary care consultations associated with long COVID was pound2.44 per patient and pound23,382,452 at the national level. Among patients with COVID-19, a long COVID diagnosis and reporting of longer-term symptoms were associated with a 43% and 44% increase in primary care consultation costs respectively, compared to patients without long COVID symptoms. Older age, female sex, obesity, being from a white ethnic group, comorbidities and prior consultation frequency were all associated with increased primary care consultation costs. CONCLUSIONS: The costs of primary care consultations associated with long COVID in non-hospitalised adults are substantial. Costs are significantly higher among those diagnosed with long COVID, those with long COVID symptoms, older adults, females, and those with obesity and comorbidities. |
|---|
| 投稿者 | Tufts, Jake; Guan, Naijie; Zemedikun, Dawit T; Subramanian, Anuradhaa; Gokhale, Krishna; Myles, Puja; Williams, Tim; Marshall, Tom; Calvert, Melanie; Matthews, Karen; Nirantharakumar, Krishnarajah; Jackson, Louise J; Haroon, Shamil |
|---|
| 組織名 | University Hospitals of Morecambe Bay NHS Foundation Trust, Lancashire, LA9 7RG,;UK.;Institute of Applied Health Research, University of Birmingham, Edgbaston,;Birmingham, B15 2TT, UK. n.guan@bham.ac.uk.;School of Population and Global Health (M431), The University of Western;Australia, 35 Stirling Highway, Perth, WA, 6009, Australia.;Birmingham, B15 2TT, UK.;Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory;Agency, London, E14 4PU, UK.;Birmingham Health Partners Centre for Regulatory Science and Innovation,;University of Birmingham, Birmingham, B15 2TT, UK.;Applied Research Collaboration (ARC) West Midlands, National Institute for Health;Research (NIHR), Birmingham, CV4 7AJ, UK.;NIHR Birmingham Biomedical Research Centre, University Hospital Birmingham and;University of Birmingham, Birmingham, B15 2TH, UK.;NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision;Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, B15;2TT, UK.;Long Covid SOS, Charity Registered in England & Wales, 11A Westland Road,;Faringdon, SN7 7EX, Oxfordshire, UK. |
|---|
